Ebele Ola
vice-president
Ebele Ola serves as the vice-president of clinical, medical, and regulatory affairs at Novo Nordisk Canada, where she emphasizes the ongoing commitment to the semaglutide molecule and its potential impact on healthcare.
Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
34,899
Power
1,561$
Sentiment
8.00
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 8.00 | 0.09% | +0% | 38,005,238 | 34,899 | $1,700,000 | 1,561$ |
| Totals | 1 | 38,005,238 | 34,899 | $1,700,000 | 1,561$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Ebele Ola, Novo Nordisk Canada’s vice-president of clinical, medical and regulatory affairs, expressed commitment to the semaglutide molecule.
8
Evan Seigerman
Per Bank
Khalid Bhatti
Dave Suchon
Farris Smith
Mathilde Merlet
Kyle Zien
Brett Belchetz
Adam Dudum
The Globe and Mail: Canada will be a launching pad for the global race for generic Ozempic